Please use this identifier to cite or link to this item:
http://dspace.bits-pilani.ac.in:8080/jspui/handle/123456789/18063Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Jain, Ankit | - |
| dc.date.accessioned | 2025-02-27T10:43:32Z | - |
| dc.date.available | 2025-02-27T10:43:32Z | - |
| dc.date.issued | 2024-08 | - |
| dc.identifier.uri | https://www.tandfonline.com/doi/full/10.1080/17425247.2024.2392799 | - |
| dc.identifier.uri | http://dspace.bits-pilani.ac.in:8080/jspui/handle/123456789/18063 | - |
| dc.description.abstract | Skin carcinoma, including malignant melanoma, basal, squamous, and Merkel cell carcinoma, present significant healthcare challenges. Conventional treatments like surgery and chemotherapy suffer from limitations like non-specificity, toxicity, and adverse effects. The upcoming treatments are dominated by nano-sized delivery systems, which improve treatment outcomes while minimizing side effects. Moving ahead, targeted nanoparticles allow localized delivery of drugs at tumor site, ensuring minimal damage to surrounding tissues. | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Taylor & Francis | en_US |
| dc.subject | Pharmacy | en_US |
| dc.subject | Skin carcinoma | en_US |
| dc.subject | Chemotherapy | en_US |
| dc.subject | Surgery | en_US |
| dc.title | Exploring the therapeutic modalities of targeted treatment approach for skin carcinoma: cutting-edge strategies and key insights | en_US |
| dc.type | Article | en_US |
| Appears in Collections: | Department of Pharmacy | |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.